Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has issued an update.
Shandong Xinhua Pharmaceutical Company Limited has released its unaudited financial results for the first quarter of 2025, showing a slight decrease in operating income by 1.81% compared to the same period last year. The company reported a significant decline in net profit attributable to shareholders, down by 20.99%, and a substantial drop in net cash flow from operating activities by 77.87%. Despite these challenges, the company’s total assets increased by 2.77%, and net assets attributable to shareholders rose by 3.28%, indicating a stable asset base.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a joint stock company based in China, primarily engaged in the pharmaceutical industry. The company focuses on the production and distribution of pharmaceutical products and related services.
YTD Price Performance: -3.10%
Average Trading Volume: 2,170,030
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.56B
See more data about 0719 stock on TipRanks’ Stock Analysis page.